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Background: The prognosis of pT1a-pT1b breast cancer (BC) used to be considered very good, with a 10-y RFS of
90%. However, some retrospective studies reported a 10-y RFS of 81%–86% and suggested benefit from adjuvant
systemic therapy.
Methods: To evaluate the variables that determined the choice of adjuvant chemotherapy and the type of
chemotherapy delivered in pT1a-pT1b BC, we analysed the small tumours enrolled in the NEMESI study.
Results: Out of 1,894 patients with pathological stage I-II BC enrolled in NEMESI, 402 (21.2%) were pT1a-pT1b.
Adjuvant chemotherapy was delivered in 127/402 (31.59%). Younger age, grading G3, high proliferative index,
ER-negative and HER2-positive status were significantly associated with the decision to administer adjuvant
chemotherapy. An anthracycline without taxane regimen was administered in 59.1% of patients, anthracycline with
taxane in 24.4%, a CMF-like regimen in 14.2% and taxane in 2.4%. Adjuvant chemotherapy was administered in
88.4% triple-negative and 73.46% HER2-positive pT1a-pT1b BC. Adjuvant trastuzumab was delivered in 30/49
HER2-positive BC (61.2%).
Conclusions: Adjuvant chemotherapy was delivered in 31.59% T1a-pT1b BC treated at 63 Italian oncological centres
from January 2008 to June 2008. The choice to deliver chemotherapy was based on biological prognostic factors.
Anthracycline-based chemotherapy was administered in 83.5% patients.
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Breast cancer is the first cause of tumour-related death in
women in Italy [1-5]. Moreover, the incidence of breast
cancer has been increasing over the last 15 years in indus-
trialised countries as the result of both Rx-mammographic
screening programs [1-5] and advances in breast cancer
awareness. The increase in incidence due to mammog-
raphy screening has been due to the increase in small T1
cancers [5,6]. In Italy, the pT1-pT1b incidence was 9.6% in
1988–1990 and 21.4% in 2005–2007 (AIRTUM, data not
published; www.registri-tumori.it): these tumours were
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reproduction in any medium, provided the origThe prognosis of these small cancers used to be con-
sidered very good, with a relapse-free survival rate at
10 years without adjuvant therapy of 90% [7-11].
However, some retrospective studies have reported a
worse outcome, with 81%–86% of relapse-free survival at
10 years [12-15]. Furthermore, Fisher et al. [16] reporting
survival data on 1,259 patients with pT1a-pT1b N0
breast cancer enrolled in 5 randomised NSABP trials,
suggested that these patients could have benefited from
adjuvant systemic therapy. Given that there is an on-
going debate on the adjuvant treatment of these
tumours, we analysed the patients with pT1a-pT1b
breast cancer enrolled in the NEMESI study, a retro-
spective observational study conducted in 2009 at 63
Italian oncological centres. We evaluated the adjuvant
systemic treatments delivered, the variables which deter-
mined the choice to administer chemotherapy, the type. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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therapy in pT1a-pT1b breast cancers.
Methods
Study design
NEMESI is a retrospective observational study conducted
at 63 Italian oncological centres. The centres were
extracted from a database of 319 oncological centres
reported in the census of the Italian Association Medical
Oncology (AIOM) [17] and stratified by geographical area
(Northern, Central, Southern Italy, including Sicily and
Sardinia) and kind of institution (public hospital, university
hospital, research institute, private hospital, other), since
these factors were considered to have an important impact
on compliance with guidelines.
The endpoints of the NEMESI study were: to describe
the adjuvant systemic treatments delivered in patho-
logical stage I-II breast cancer, to evaluate the variables
which determined the choice of adjuvant chemotherapy
and the type of chemotherapy, to evaluate compliance
with the treatment administered, and to compare the
practice observed in Italian clinical settings with that
proposed by international guidelines.
Criteria of eligibility were: women age ≥18 years;
histological diagnosis of invasive breast cancer stage
I-II (AJCC version VI) [18] who underwent surgery;
at least one cycle of adjuvant chemotherapy and/or
adjuvant hormonal therapy; availability of the follow-
ing local staging and biological parameters: pT, pN,
grading, estrogen receptor (ER), progesterone recep-
tor (PgR), proliferative index (Ki67 or MIB-1), HER2.
Candidates for adjuvant therapy with trastuzumab
and/or radiotherapy on residual breast or thoracic
wall and/or regional supraclavicular and/or internal
breast lymph node stations were also eligible. Exclu-
sion criteria were: neo-adjuvant chemotherapy and/or
hormonal therapy, locally advanced and/or metastatic
(stage III-IV) breast cancer, and in-situ carcinoma.
Data were retrospectively retrieved by each site from
the patients’ clinical records.
The protocol was reviewed by the independent ethics
committee of the coordinating centre and notification of
the study was sent to the ethics committees of each par-
ticipating centre [19]. The protocol complied with the
recommendations of the 18th World Health Congress
(Helsinki, 1964) [20].
Sample size determination and data collection
The study aimed at collecting data from the clinical
records of not less than 1,300 and not more than 1,500
patients attending at least 50 oncologic centres. These
figures correspond to 3.6% and 4.2% respectively of the
new cases of early stage breast cancer recorded each year
in Italy (about 40,000 cases, 90% of which are earlystage), and 12.5% of the Italian oncologic sites (about
400 throughout Italy).
Each centre was requested to collect, within December
2009, the data of a minimum of ten and a maximum of
30 consecutive patients with early breast cancer between
1 January 2008 and 30 June 2008; with the only require-
ment being to collect the data of at least 33% of the
patients undergoing adjuvant chemotherapy. This re-
quirement was mandatory because the primary objective
of the study was not to assess how many patients
received adjuvant chemotherapy within that period but
to identify the biological, staging and demographic para-
meters that determined: (i) whether adjuvant chemother-
apy would be prescribed, and (ii) the type and schedule
of chemotherapy selected. To ensure anonymity, the per-
centage of patients enrolled in the study could not ex-
ceed 50% of the patients attending the centre during the
study period. According to the study protocol, central re-
vision of all tissue samples was not done.
The data, collected on an electronic clinical report
form, were submitted to automatic checks to assess com-
pleteness, correctness and internal coherence. Possible
discrepancies or otherwise unreliable data were submit-
ted to the investigator in the form of queries for clarifica-
tion and/or resolution.
Variables evaluated
In the NEMESI study patient and tumour characteristics,
type of local-regional treatment and adjuvant systemic
therapy, and compliance to chemotherapy were evaluated.
In this NEMESI sub-study, only the pT1a-pT1b breast
cancers were analysed. We evaluated: patient characteris-
tics (age class, menopausal status), stage according to the
TNM AJCC version VI classification, bio-pathological
characteristics of the primitive tumour (histology, vascular
invasion, grading, ER, PgR, HER2, and the proliferative
index), type of surgery, adjuvant systemic therapy (chemo-
therapy, hormonal therapy, trastuzumab, concurrent adju-
vant treatment with other experimental drugs), the
variables associated with choice of administered adjuvant
chemotherapy and compliance to chemotherapy. More-
over, in HER2-positive small tumours the variables asso-
ciated with choice of administered adjuvant chemotherapy
and trastuzamab were analysed.
Statistical methods
In this survey 402 patients were examined with pT1a-
pT1b breast tumour stage from a total of 1,894
patients enrolled in the NEMESI clinical study. The
analysis was performed considering not only the refer-
ence population but also various subgroups decided in
accordance with different analysis purposes. For most
of these groups both descriptive analysis and inferen-
tial analysis were performed. As a descriptive analysis,
T1 T2
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tive statistics, including number of subjects: mean,
standard deviation, and median, while for categorical
variables summaries included counts of subjects and
percentages. Pearson’s Chi-Square (χ2) test was per-
formed in order to evaluate whether the frequency
distribution of certain events observed in a sample
(for example variables as age, menopausal status,
grading, ER status) is consistent with their theoretical
distributions. Chi-Square test for Specified Proportions
was used to compare, in one way frequency tables,
the homogeneity proportion between the general
population (pathological stage I-II with the exclusion
of pT1a, pT1b, considered as a reference distribution)
and the distribution of the same variables in the sub-
group of pT1a-pT1b patients. For both tests, the sig-
nificance level used was equal to p = 0.05.
Multivariate logistic regression analysis was performed
to assess the relationship between clinical and demo-
graphic variables and the type and treatment schedule of
adjuvant chemotherapy administered with many covari-
ates: age class, menopausal status, vascular invasion,
ECOG performance status, type of surgery, TNM stage,
ER, PgR, HER2 status, proliferative index. The logistic
model contained only categorical variables. The continu-
ous variables (e.g. proliferative index, ER, PgR, HER2)
were categorized in different classes according to inter-
national indications.
The selection of variables to include in the model was
defined using the stepwise procedure with a significant
level of p = 0.05 to include variables in the model. In the
logistic model the odds ratio estimates and their 95%
confidence limits were also calculated. All statistical ana-
lysis was performed using SAS (Statistical Analysis
System, SAS Institute Inc., Cary, NC, USA) version 9.1.3
for Windows.
Results
In the NEMESI study 1,894 patients with patho-
logical stage I-II breast cancer were enrolled by 63
Italian centres. Out of 1,894 cases included in this
survey, 402 (21.2%) were pT1a-pT1b breast cancers.
Patient and tumour characteristics are reported in
Tables 1 and 2; no considerable relevant differences
were observed between pT1a-pT1b breast cancers.
Conservative breast surgery and node sentinel biopsy
were performed in 86% and in 79.3% of pT1a-pT1b
tumours, respectively (Table 1). The majority of the
tumours were pN0 (78.8%) and showed G1-G2 grad-
ing (80.6%), absence of vascular invasion (67.5%), low
proliferative index (71.8%), hormonal status positive
(89.7%), HER2-status negative (88.12%) (Table 2).
Patients and tumour characteristics of 402 pT1a-
pT1b breast cancers were compared to 1,492 ≥pT1ctumours of NEMESI study (Table 3). The following
variables were distributed in a statistically different
manner between the groups: menopausal status
(p = 0.015), conservative surgery (p <0.0001), grading
(p< 0.0001), proliferative index (p< 0.0001), ER sta-
tus (p = 0.02), hormonal receptor status (p = 0.006)
and HER2 status (p = 0.009). Analysing the different
categories of the statistically significant variables, it
was observed that in 402 pT1a-pT1b breast cancers
compared to other 1,492 cases, there were higher
percentages of: postmenopausal patients (72.8% vs
68%; p = 0.05), tumours that underwent conservative
surgery (86.7% vs 72.5%; p = 0.005) and sentinel node
biopsies (79.4% vs 60.5%; p< 0.0001), tumours with
grading G1 (25.1% vs 8.0%; p< 0.0001) and with a
low proliferative index (70.6% vs 47.4%; p <0.0001).
In the pT1a-pT1b tumours a lower incidence of
prognostic biological factors associated with poor progno-
sis was observed: ER-negative status (12.7% vs 18.5%;
p = 0.01), ER and PgR negative status (11.9% vs 17.9%;
p = 0.01), and HER2-positive status (12.2% vs 18.7%;
p = 0.006). These small breast cancers (≤ 1 cm) showed a
higher percentage of pN0 (79.4% vs 56%; p <0.0001) com-
pared to 1,492 ≥pT1c tumours of the NEMESI study.
Adjuvant chemotherapy was delivered in 127 out of
402 patients (31.59%) with pT1a-pT1b breast cancer: in
27 of 82 pT1a tumours (32.9%) and in 100 of 320 pT1b
tumours (31.25%). Patients and tumour characteristics
were analysed to evaluate their influence on the decision
to administer or not adjuvant chemotherapy (Table 4).
Seventy-two out of 127 patients treated with chemother-
apy were pN0 (56.69%). The multivariate logistic model
analysis showed that younger age, grading G3, high pro-
liferative index (≥ 30% Ki-67/Mib 1), ER negative status
and HER2-positive status were significantly associated
with the decision to administer adjuvant chemotherapy
(Table 5).
The multivariate logistic analysis confirmed that ER
negative status, high proliferation index, and HER2-
positive status were significantly associated with the
decision to administer adjuvant chemotherapy in
patients with pT1b (Table 6), while it could not be
performed for pT1a due to the low number of
patients (=27). Both analyses excluded the evaluation
of axillary lymph node status from the model fit be-
cause the distribution of population was unbalanced
and it was impossible to estimate the values for the
different categories.
We analysed the types of adjuvant chemotherapy
administered in 127 patients with pT1a-pT1b tumours.
Anthracycline without taxane regimen was administered
in 59.1% of patients, anthracycline with taxane in 24.4%,
CMF-like in 14.2% and taxane without anthracycline in
only 2.4% (Table 7).
Table 1 Patient characteristics and treatment
Total (pT1a and pT1b) pT1a pT1b
N. of patients 402 82 320
Distribution by age
18–34 7 (1.7%) 2 (2.4%) 5 (1.6%)
35–49 85 (21.1%) 19 (23.2%) 66 (20.6%)
50–69 230 (57.2%) 47 (57.3%) 183 (57.2%)
≥ 70 80 (19.9%) 14 (17.1%) 66 (20.6%)
Menopausal status
Pre- 101 (25.1%) 25 (30.5%) 76 (23.8%)
Post- 293 (72.9%) 54 (65.9%) 239 (74.6%)
Missing 8 (2.0%) 3 (3.6%) 5 (1.6%)
Surgery:
Breast conservative surgery 346 (86.0%) 65 (79.3%) 281 (87.8%)
Mastectomy 56 (13.9%) 17 (20.7%) 39 (12.2%)
Node sentinel biopsy
Yes 319 (79.4%) 64 (78.0%) 255 (79.7%)
No 83 (20.6%) 18 (22.0%) 65 (20.3%)
Axillary nodal dissection
Yes 137 (34.1%) 31 (37.8%) 106 (33.1%)
No 265 (65.9%) 51 (62.2%) 214 (66.9%)
Radiotherapy
Yes 317/402 (78.9%) 58/82 (70.7%) 259/320 (81.0%)
No 85/402 (21.1%) 24/82 (29.3%) 61/320 (19.0%)
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different adjuvant chemotherapy regimens did not allow
for a statistical evaluation of the patient and tumour char-
acteristics which could have influenced the choice of adju-
vant chemotherapy type.
In the few older patients (≥ 70 years) treated with
chemotherapy, a CMF-like regimen was administered in
50%; in none of these patients was anthracycline and tax-
ane-based adjuvant therapy chosen. A CMF-like regimen
was chosen more frequently in postmenopausal patients
(18.1% vs 9.6%), in patients with grade G1 tumours
(22.2% vs 12.2% G3) and in patients with cancers having
low or moderate proliferative indexes (14.5% and 25% re-
spectively, versus 4.9% high proliferative index). In pT1b
tumours, anthracycline and taxane-based regimen was
chosen more frequently than in pT1a breast cancers
(28% in pT1b vs 11.1% in pT1a) (Table 7).
Regarding compliance to adjuvant chemotherapy, it
was observed that 105 of 127 patients (82.67%) received
4–6 cycles. Delays (> 7 days versus planned), were
reported in 20 patients (15.7%), with a median delay of
7 days (range 7–28). The definitive interruption of
chemotherapy occurred in only eight patients: three due
to toxicity or severe adverse event, four due to the
patient’s decision and one due to the investigator’s
decision.Hormonal therapy, planned in 351 of the 354 patients
with hormonal receptor-positive tumours, was administered
in 346 patients (97.7%). In pT1a-pT1b breast cancers, tam-
oxifen with or without LHRH was the hormonal therapy
more frequently administered (85.3%) in premenopausal
patients; aromatase inhibitors for 5 years (67.3%) was the
endocrine treatment more often utilised in the postmeno-
pausal setting, where tamoxifen for 2–3 years followed by
aromatase inhibitor for 3–2 years was administered in
17.1% of patients (Table 8).
Adjuvant chemotherapy in triple-negative pT1a and pT1b
tumours
Triple-negative (ER= 0%, PgR=0%, HER2-negative) pT1a-
pT1 b tumours were 26 (6.5%); 2 were pT1a and 24 were
pT1b. Adjuvant chemotherapy was administered in 88.4%
of patients (23/26): in 1 of 2 patients with pT1a (50%) and
in 22 of 24 pT1b patients (91.66%). A CMF-like regimen
was administered in 6 patients (26.1%), anthracycline with-
out taxane in 11 (47.8%), anthracycline with taxane in 5
(21.7%) and taxane without anthracycline in 1 (4.3%).
Adjuvant chemotherapy and adjuvant trastuzumab in
pT1a and pT1b HER2-positive breast cancers
Forty-nine pT1a-pT1b tumours were HER2-positive
(12.1%). Adjuvant chemotherapy was delivered to 36 of
Table 2 Biopathological characteristics
Total (pT1a and pT1b) pT1a pT1b
N. of patients 402 82 320
Histology
Ductal 336 (83.6%) 70 (85.4%) 266 (83.1%)
Lobular 38 (9.5%) 7 (8.5%) 31 (9.7%)
Mixed 5 (1.2%) 0 (0.0%) 5 (1.6%)
Other 23 (5.7%) 5 (6.1%) 18 (5.6%)
Vascular invasion
Yes 30 (7.5%) 3 (3.7%) 27 (8.4%)
No 267 (66.4%) 51 (62.2%) 216 (67.5%)
Unknown 105 (26.1%) 28 (34.1%) 77 (24.1%)
Grading
G1 101 (25.1%) 18 (22.0%) 83 (25.9%)
G2 221 (55.0%) 46 (56.1%) 175 (54.7%)
G3 72 (17.9%) 15 (18.3%) 57 (17.8%)
Unknown 8 (2.0%) 3 (3.7%) 5 (1.6%)
Proliferation index (Ki-67/MB1)
0–18% 283 (70.5%) 53 (64.6%) 230 (71.8%)
19–29% 52 (12.9%) 17 (20.7%) 35 (10.9%)
≥ 30% 54 (13.4%) 7 (8.5%) 47 (14.7%)
Unknown 13 (3.2%) 5 (6.1%) 8 (2.5%)
ER status
ER positive (≥ 10%) 351 (87.3%) 65 (80.5%) 285 (89.1%)
ER negative (0–9%) 51 (12.7%) 16 (19.5%) 35 (10.9%)
PgR status
PgR positive (≥ 10%) 300 (74.6%) 54 (65.9%) 246 (76.9%)
PgR negative (0–9%) 102 (25.4%) 28 (34.1%) 74 (23.1%)
Hormonal status*
ER and/or PgR positive 354 (88.1%) 65 (81.7%) 287 (89.7%)
ER and PgR negative 48 (11.9%) 15 (18.3%) 33 (10.3%)
HER2 status**
Positive 49 (12.2%) 19 (23.2%) 30 (9.3%)
Negative 344 (85.6%) 62 (75.6%) 282 (88.2%)
Unknown 9 (2.2%) 1 (1.2%) 8 (2.5%)
pN status
pN0 319 (79.4%) 67 (81.7%) 252 (78.8%)
pN1 (1–3) 74 (18.4%) 12 (14.6%) 62 (19.4%)
pN2 (4–9) 6 (1.5%) 2 (2.4%) 4 (1.3%)
pN3 (≥ 10) 3 (0.7%) 1 (1.2%) 2 (0.6%)
* cut off: 10%
** HER2 status positive if: IHC 3+; or IHC 2+ and amplified by FISH,SISH,CISH; or amplified by FISH,SISH,CISH.
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23/130 pT1b (76.6%). Patient and tumour characteristics
are reported in Table 9. Adjuvant chemotherapy was
administered in 100% (19/19) of the younger patients
(18–49 years) and in 100% (6/6) of patients with meta-
static lymph nodes, in 90% (18/20) of tumours with
negative hormonal receptors, and 69.6% and 84.2% of G2
and G3 tumours, respectively.We observed that 30 out of 36 patients treated with adju-
vant chemotherapy were pN0 and in these patients the
choice of administered chemotherapy was independent of
other patient and tumour characteristics and based only on
HER2-positivity. An anthracycline-based regimen was
administered in 34 of 36 HER2-positive patients (94.4%)
(anthracycline without taxane in 72.2% and anthracycline
with taxane in 22.2%); a CMF-like regimen in 1 patient
Table 3 Patient and tumour characteristics of pT1a-pT1b
tumours vs other stage I-II tumours in the NEMESI study
Pathological stage I-II (pT1a, pT1b
excluded)
pT1a,
pT1b
N. of patients 1492 402
Distribution by age
18–34 23 (1.5%) 7 (1.7%)
35–49 384 (25.7%) 85
(21.1%)
50–69 754 (50.5%) 230
(57.2%)
≥ 70 331 (22.2%) 80
(19.9%)
Menopausal status
Pre- 465 (31.2%) 101
(25.1%)
Post- 1,014 (68.0%) 293
(72.8%)
Unknown 13 (0.9%) 8 (2.0%)
Node sentinel biopsy
Yes 903 (60.5%) 319
(79.3%)
No 589 (39.5%) 83
(20.7%)
Axillary nodal
dissection
Yes 941 (63.1%) 137
(34.1%)
No 551 (36.9%) 265
(65.9%)
Grading
G1 120 (8.0%) 101
(25.1%)
G2 741 (48.7%) 221
(55.0%)
G3 589 (39.5%) 72
(17.9%)
Unknown 42 (2.8%) 8 (2.0%)
Proliferation index (Ki-
67/MB1)
0–18% 707 (47.4%) 283
(70.6%)
19–29% 279 (18.7%) 52
(12.9%)
≥ 30% 461 (30.9%) 54
(13.4%)
Unknown 45 (3.0%) 13 (3.2%)
ER status
ER positive (≥ 10%) 1,215 (81.4%) 351
(87.3%)
ER negative (0–9%) 276 (18.5%) 51
(12.7%)
Unknown 1 (0.1%) 0 (0.0%)
PgR status
PgR positive (≥ 10%) 1,038 (69.6%) 300
(74.6%)
Table 3 Patient and tumour characteristics of pT1a-pT1b
tumours vs other stage I-II tumours in the NEMESI study
(Continued)
PgR negative (0–9%) 449 (30.1%) 101
(25.4%)
Unknown 5 (0.3%) 0 (0.0%)
Hormonal status*
ER and/or PgR positive 1,228 (82.3%) 354
(88.1%)
ER and PgR negative 263 (17.6%) 48
(11.9%)
Unknown 1 (0.1%) 0 (0.0%)
HER2 status**
Positive 279 (18.7%) 49
(12.2%)
Negative 1,185 (79.4%) 344
(85.6%)
Missing 28 (1.9%) 9 (2.2%)
pN status
pN0 836 (56.0%) 319
(79.4%)
pN1 (1–3) 477 (32.0%) 74
(18.4%)
pN2 (4–9) 113 (7.6%) 6 (1.5%)
pN3 (≥ 10) 66 (4.4%) 3 (0.7%)
* cut off: 10%
** HER2 status positive if: IHC 3+; or IHC 2+ and amplified by FISH,SISH,CISH; or
amplified by FISH,SISH,CISH.
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In 30 out of 36 patients treated with chemotherapy, also ad-
juvant trastuzumab was administered. Trastuzumab was
delivered in all six patients with lymph node involvement
and in 24 patients with pN0 disease (Table 9).
Discussion
In the NEMESI study, a retrospective study which
enrolled 1,894 pathological stage I-II breast cancers,
402 pT1a-pT1b tumours were included. A multivari-
ate analysis conducted to evaluate the influence of
patient and tumour characteristics on the decision to
administer or not adjuvant chemotherapy in pT1a-
pT1b breast cancers, showed that younger age, grad-
ing G3, high proliferative index, ER-negative status
and HER2-positive status were significantly asso-
ciated with the decision to administer adjuvant
chemotherapy. In the patients treated with adjuvant
chemotherapy, an anthracycline-based regimen was
administered in 83.5% (anthracycline without taxane
in 59.1% and anthracycline with taxane in 24.4%)
while a CMF-like regimen was administered in only
13.38%. In our study compliance to adjuvant chemo-
therapy was high (82.67% of patients received 4–6
planned cycles) and the definitive interruption of
chemotherapy occurred in only eight patients.
Table 4 Adjuvant chemotherapy and patient/tumour
characteristics
pT1a, pT1b
total patients
(N = 402)
Patients treated with
adjuvant chemotherapy
(N = 127)*
Distribution by age
18–34 7/402 (1.7%) 6/7 (85.7%)
35–49 85/402 (21.1%) 46/85 (54.1%)
50–69 230/402 (57.2%) 67/230 (29.1%)
≥ 70 80/402 (19.9%) 8/80 (10.0%)
Menopausal status
Pre- 101/402 (25.1%) 52/101 (51.5%)
Post- 293/402 (72.8%) 72/293 (24.6%)
Unknown 8/402 (2.0%) 3/8 (37.5%)
Grading
G1 101/402 (25.1%) 9/101 (8.9%)
G2 221/402 (55.0%) 66/221 (29.8%)
G3 72/402 (17.9%) 49/72 (68.0%)
Unknown 8/402 (2.0%) 3/8 (37.5%)
Proliferation index (Ki-67/MB1)
0–18% 283/402 (70.6%) 55/283 (19.4%)
19–29% 52/402 (12.9%) 28/53 (52.8%)
≥ 30% 54/402 (13.4%) 41/54 (75.9%)
Unknown 13/402 (3.2%) 3/13 (23.0%)
ER status
ER positive (≥ 10%) 351 /402(87.3%) 82/351(23.6%)
ER negative (0–9%) 51/402(12.7%) 45/51 (88.2%)
Hormonal status*
ER and/or PgR positive 354 /402 (74.6%) 84/354 (24.0%)
ER and PgR negative 48/402 (25.4%) 43/48 (89.6%)
HER2 status**
Positive 49/402 (12.2%) 36/49 (73.5%)
Negative 344/402 (85.6%) 90/344 (26.2%)
Missing 9/402 (2.2%) 1/9 (11.1%)
pN status
pN0 319/402 (79.4%) 72/319 (22.6%)
pN1 (1–3) 74/402 (18.4%) 47/74 (63.5%)
pN2 (4–9) 6/402(1.5%) 5/6 (83.3%)
pN3 (≥ 10) 3/402 (0.7%) 3/3 (100%)
* cut off: 10%.
** HER2 status positive if: IHC 3+; or IHC 2+ and amplified by FISH,SISH,CISH; or
amplified by FISH,SISH,CISH.
Table 5 Results of the multivariate logistic model analysis
evaluating the probability of being treated with adjuvant
chemotherapy for pT1a and pT1b breast cancers
Variable Odds ratio 95% CI P value
Age range (years) 0.0185
≥70 1
18–34 NE NE
35–49 8.22 2.00-33.67
50–70 2.44 0.69-8.58
Grading 0.024
G1 1
G2 3.48 0.56-5.01
G3 8.33 1.82-33
ER receptor 0.0007
Positive 1
Negative 11.43 2.78-47.03
Proliferative index 0.001
Low 1
Medium 2.08 0.28-16
High 9.10 2.57-33
HER2 0.002
Negative 1
Positive 9.09 2.73-33.3
NE, not evaluable due to the small sample in this category.
Table 6 Results of the multivariate logistic model analysis
evaluating the probability of being treated with adjuvant
chemotherapy for pT1b breast cancers
Variable Odds ratio 95% CI P value
ER receptor 0.001
Positive 1
Negative 21.30 3.40-133.28
Proliferative index <0.0001
Low 1
Medium 15 0.86-21.31
High 20 5.56-100
HER2 <0.0001
Negative 1
Positive 20 4.35-100
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with no axillary lymph node involvement is controversial.
The risk of relapse is related to stage of tumour (tumour
size and lymph node status) and to biological character-
istics. Therefore, in pT1a-pT1b tumours, which are pN0
in 82%–85% of the cases, the biological markers are uti-
lised during treatment decision-making. In our study, the
variables significantly associated with the decision to ad-
minister adjuvant chemotherapy in pT1a-pT1b breastcancers were younger age and the biological markers
associated with a poor prognosis (grading G3, high pro-
liferative index, ER-negative status and HER2-positive
status) [14,16,21-28], and also predictive of chemore-
sponsivity in the neoadjuvant setting.
Several changes in indication to adjuvant systemic ther-
apy occurred for patients with node-negative tumours ≤
1 cm in size according to 1998–2007 St Gallen Consensus
Conference guidelines. In the 1998 St Gallen Consensus
Conference the population with <10% of relapse was not
Table 8 Type of hormonal therapy administered
according to menopausal status in 346 pT1a and pT1b
tumours
Premenopausal
(N =89)
Postmenopausal
(N = 257)
Hormonal therapy
Tamoxifen 5 y 11 (12.3%) 35 (13.6%)
Tamoxifen
5 y + LHRH
65 (73.0%) 0 (0.0%)
Tamoxifen
2-3y!Aromatase
Inhibitor 3–2 y
3 (3.3%) 44 (17.1%)
Aromatase
Inhibitor 5 y
1 (1.1%) 173 (67.3%)
Aromatase Inhibitor
5 y + LHRH
6 (6.7%) 1 (0.4%)
LHRH alone 1 (1.1%) 0 (0.0%)
Other 2 (2.2%) 4 (1.6%)
Table 7 Type of chemotherapy administered in 127
patients with pT1a, pT1b breast cancers
All pts
(N =127)
pT1a pts
(=27)
pT1b pts
(N = 100)
Regimen
CMF-like 18/127 (14.2%) 3/27 (11.1%) 15/100 (15%)
Anthracycline
without taxane
75/127 (59.1%) 21/27 (77.8%) 54/100 (54%)
Anthracycline
with taxane
31/127 (24.4%) 3/27 (11.1%) 28/100 (28%)
Taxane
without anthracycline
3/127 (2.4%) 0 3/100 (3%)
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Consensus Conference made a fundamental change in the
algorithm for the selection of adjuvant systemic therapy
for early breast cancer, considering first endocrine respon-
siveness and then the risk of relapse. The risk allocation of
tumours below 1 cm in size and negative nodes remained
still controversial [30]. The 2007 St Gallen Consensus
Conference [31] utilised the biological factors associated to
worse prognosis, considered singularly or together, to
identify the endocrine non responsive tumours suitable for
only adjuvant chemotherapy, and to identify the incom-
pletely or highly endocrine responsive tumours suitable,Table 9 Adjuvant chemotherapy and adjuvant trastuzumab b
pT1a and pT1b breast cancers (n = 49)
All HER2-positive
tumours
No. of patients 49
Menopausal status
pre- 19
post- 30
Age (years)
18–34 2
35–49 17
50–69 25
≥ 70 5
Hormonal receptor status
positive 29
negative 20
LN status
pN0 43
pN1 4
pN2 2
Grading
G1 2
G2 23
G3 19
* Values and percentages are based on the all HER2-positive patientsaccording to risk of relapse, for addition of adjuvant
chemotherapy to hormonal therapy, irrespective of tumour
size. However, some but not all panel members viewed
pT≤1 cm tumours with node-negative disease as repre-
senting low risk even if higher grade and/or younger age.
The NCCN Practice Guidelines 2007 [www.nccn.org]y tumour and patient characteristics in HER2-positive
HER2-positive tumours
treated with adjuvant
chemotherapy*
HER2-positive tumours treated
with adjuvant chemotherapy
and trastuzumab *
36 (73.5%) 30 (61.2%)
18 (94.7%) 14 (73.7%)
18 (60.0%) 16 (53.3%)
2 (100.0%) 2 (100.0%)
17 (100.0%) 12 (70.6%)
16 (64.0%) 15 (60.0%)
1 (20.0%) 1 (20.0%)
18 (62.1%) 15 (51.7%)
18 (90.0%) 15 (75.0%)
30 (69.7%) 24 (55.8%)
4 (100.0%) 4 (100.0%)
2 (100.0%) 2 (100.0%)
1 (50.0%) 0 (0.0%)
16 (69.6%) 13 (56.5%)
16 (84.2%) 16 (84.2%)
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between 6 mm and 10 mm without metastases in lymph
nodes (pT1b pN0): in ER-negative pT1b pN0 (both HER2-
negative and HER2-positive) and, in addition to hormonal
therapy, in ER positive pT1b pN0 moderate/poorly differ-
entiated or with unfavourable features (both HER2-nega-
tive and HER2-positive).
We report that an anthracycline-based regimen was
administered in 83.5% of patients (anthracycline without
taxane in 59.1% and anthracycline with taxane in 24.4%)
while CMF-like anthracycline-regimens (without or with
taxane) highlights that if the decision was to administer
chemotherapy, the most active regimen was selected,
also in small breast cancers. This trend was observed
also in all patients with stage I-II breast cancer enrolled
in the NEMESI study [32] as well as in the NEMESI sub-
group of triple-negative tumours [33].
Our study has some limits. Although the majority of
pT1a-pT1b breast cancers had favourable prognostic fac-
tors, as reported in other retrospective studies [7-11], adju-
vant chemotherapy was delivered in 31.59% of patients.
This percentage is considerable but may not reflect the
clinical practice and must be evaluated considering both
the eligibility criteria of NEMESI (the patients enrolled
must have received at least one cycle of adjuvant chemo-
therapy and/or adjuvant hormonal therapy) and the re-
quirement that each centre had to collect the data of at
least 33% of the patients undergoing adjuvant chemother-
apy. It is necessary consider this limit also when we
reported that 36 out of 49 patients with HER2-positive
small breast cancer were treated with adjuvant chemother-
apy (73.46%). Thirty out of these 36 HER2-positive
patients were pN0 and in these patients the choice of
administered chemotherapy was independent of other pa-
tient and tumour characteristics and based only on HER2-
positivity, considered a poor prognostic factor [22-24], as
well confirmed by recent studies [25-28]. Adjuvant trastu-
zumab was administered in 30 of 36 patients who received
chemotherapy. HER2-positivity is a predictive factor of
trastuzumab response, but although five out of six rando-
mised phase III trials reported marked benefit of adjuvant
trastuzumab for disease-free and overall survival (with re-
duction of recurrence and mortality by 20-40%) [34-38],
there are no data on trastuzumab in pT1a-pT1b HER2-
positive breast cancer. On the other hand, there is indirect
evidence. In the BCIRG006 and HERA subgroup analyses
adjuvant trastuzumab did not result in different rates of
risk reduction among HER2-positive breast cancers in
function of nodal status or tumour size [35,39,40]. More
data supporting the use of adjuvant trastuzumab in small
node-negative HER2-positive breast cancer emerged from
three recently reported retrospective investigations. In a
French multicenter series from 2002 to 2008, 97 patients
with pT1a,b pN0 HER2-positive tumours were identified.Forty-one patients (42%) had been treated with adjuvant
trastuzumab-based therapy with (n= 38) or without (n= 3)
chemotherapy [41]. The decision to administer adjuvant
trastuzumab was significantly associated with a negative
hormonal receptor status, a high Eltson-Ellis grade, a
moderate/high mitotic index, and the date of the diagnosis
(before or after the HERA results were released). With a
median follow-up of 29 months, there were no recurrences
in patients treated with trastuzumab-based therapy while
5 of 56 patients who did not receive trastuzumab had
developed a recurrence. Another single-institution retro-
spective study included 485 women with node-negative,
HER2-positive tumours ≤2 cm treated in the pre- (2002–
2004) and post- (2005–2008) trastuzumab era [42]. Events
of disease recurrence were more frequent in the pre-tras-
tuzumab group as compared with the post-trastuzumab
group. A third study reported the breast cancer specific 5-
year survival of HER2-positive pT1a and pT1b pN0 breast
cancer in 20,188 patients identified in the California Can-
cer Registry [43]. It was significantly shorter among HER2-
positive breast cancer compared to HER2-negative
patients (p= 0.0001) in the 2000–2004 era, while there was
no difference in the 2005–2007 era, after the introduction
in clinical practice of adjuvant trastuzumab.
The 2007 St Gallen Consensus Conference did not rec-
ommend adjuvant trastuzumab in women with a primary
tumour< 1 cm in size and with no axillary node involve-
ment [31], and also the 2007 NCCN Guidelines did not
indicate trastuzumab in tumours <1 cm. On the other
hand, the more recent version of the NCCN Guidelines
2011 (v.2.2011) recommend the use of adjuvant trastuzu-
mab in women with node-negative tumours (both HR-posi-
tive and HR-negative) that are 0.6 to 1.0 cm as category 2A
recommendation, because patients with tumours 1 cm or
smaller and node negative were not consistently included in
the available clinical trials. The majority of the Panel mem-
bers of the 2011 St Gallen Consensus Conference were will-
ing to extended adjuvant trastuzumab to patients with
pT1b, but not pT1a pN0 disease [44].
Moreover, hormonal therapy, planned in 351 patients
out of 354 hormonal receptor-positive pT1a-pT1b
tumours, was administered in 346 patients (97.7%).
These data are very different from those reported by an
audit of clinical practice in Italy conducted in March
2000 regarding adjuvant systemic therapies prescribed
for breast cancer. In this audit it resulted that endocrine
therapy was not prescribed in 102 out of 541 patients
(19%) with endocrine-responsive disease [45].
Conclusions
In conclusion, the choice to deliver adjuvant chemotherapy
to patients with pT1a-pT1b breast cancer treated at 63 Ital-
ian oncological centres from January 2008 to June 2008 was
based on tumour biology. When it was decided to
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http://www.biomedcentral.com/1471-2407/12/158administer adjuvant chemotherapy, the most active regi-
mens, anthracycline-based, were selected. Compliance to
treatment was excellent.
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